14. Intangible Assets Other than Goodwill
(thousands of €) |
Software & |
Licenses, rights, technology and |
Exclusive rights |
Contract costs |
Total |
|---|---|---|---|---|---|
Acquisition value |
|
|
|
|
|
|
|
|
|
|
|
On January 1, 2023 |
27,377 |
44,258 |
89,720 |
15,384 |
176,740 |
Additions |
567 |
|
|
|
567 |
Sales and disposals |
(930) |
(948) |
|
|
(1,878) |
Translation differences |
|
(139) |
|
|
(139) |
On December 31, 2023 |
27,014 |
43,171 |
89,720 |
15,384 |
175,290 |
Additions |
666 |
|
64,725 |
|
65,391 |
Sales and disposals |
(1,863) |
(3,613) |
|
|
(5,476) |
Translation differences |
|
246 |
|
|
246 |
On December 31, 2024 |
25,817 |
39,804 |
154,445 |
15,384 |
235,451 |
|
|
|
|
|
|
Amortization and impairment |
|
|
|
|
|
|
|
|
|
|
|
On January 1, 2023 |
15,210 |
3,896 |
6,154 |
5,126 |
30,387 |
Amortization |
4,291 |
1,426 |
11,637 |
1,538 |
18,892 |
Sales and disposals |
(927) |
(948) |
|
|
(1,875) |
Translation differences |
|
(20) |
|
|
(20) |
On December 31, 2023 |
18,574 |
4,354 |
17,791 |
6,664 |
47,384 |
Amortization |
4,384 |
493 |
22,198 |
1,538 |
28,613 |
Sales and disposals |
(1,863) |
(3,613) |
|
|
(5,476) |
Translation differences |
|
68 |
|
|
68 |
On December 31, 2024 |
21,095 |
1,302 |
39,989 |
8,202 |
70,589 |
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
|
|
|
On December 31, 2023 |
8,440 |
38,817 |
71,929 |
8,720 |
127,906 |
On December 31, 2024 |
4,722 |
38,502 |
114,456 |
7,182 |
164,862 |
Through the acquisition of CellPoint and AboundBio in June 2022, we acquired in-process research and development related to two CAR-T product candidates (€28.2 million on December 31, 2024, and on December 31, 2023) , exclusive rights and technology, being a fully human therapeutics platform. These exclusive rights refer to our exclusivity contract with Lonza (€60.3 million on December 31, 2024, €71.9 million on December 31, 2023) and are depreciated until the beginning of March 2030, in accordance with the contract.
The addition in exclusive rights in 2024 refers to the upfront exclusivity consideration paid to Adaptimmune of $70.0 million, which is amortized over the expected exclusivity period until the end of 2027.
On December 31, 2024, our statement of financial position did not hold any internally generated assets capitalized as intangible asset.